Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection

Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection


Lead sponsor: Bagcilar Training and Research Hospital

Source Bagcilar Training and Research Hospital
Brief Summary

Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease.

In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease.

In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.

Overall Status Completed
Start Date July 2012
Completion Date January 2017
Primary Completion Date January 2013
Study Type Observational
Primary Outcome
Measure Time Frame
Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks
Enrollment 480

Sampling method: Non-Probability Sample


Inclusion Criteria:

Patients with LUTS and elevated serum PSA levels and/or suspicious rectal examination

Exclusion Criteria:

usage of zinc included drugs, older prostatic operations, older prostatic radiotherapy, older prostatic biopsies, chronic rectal diseases (anal fissure, hemorrhoid, etc..), PIN(prostatic intraepithelial neoplasia) and ASAP(atypical small acinar proliferation) in pathologic evaluation.

Gender: Male

Minimum age: N/A

Maximum age: N/A

Healthy volunteers: No

Bagcilar Training and Research Hospital-Depertmant of Urology
Location Countries


Verification Date

November 2017

Responsible Party

Responsible party type: Principal Investigator

Investigator affiliation: Bagcilar Training and Research Hospital

Investigator full name: Mustafa Zafer Temiz

Investigator title: resident

Has Expanded Access No
Condition Browse
Arm Group

Arm group label: prostate cancer

Description: prostate adenocarcinoma in pathologic evaluation

Arm group label: control

Description: benign prostatic diseases in pathologic evaluation

Study Design Info

Observational model: Case-Control

Time perspective: Prospective

Source: ClinicalTrials.gov